I-PEN® Osmolarity System Now Available in Brazil Through Partnership with DryCom MONTREAL, March 26, 2019 (GLOBE NEWSWIRE) -- I-MED Pharma, Inc., a Canadian company specializing in dry eye diagnosis and management, announced today the signing of an exclusive agreement with...

I-MED Pharma Inc. Announces Partnership with Medicals International MONTREAL, July 23, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of an exclusive agreement with...

I-MED Pharma’s I-PEN® Receives Regulatory Approval from INVIMA in Colombia and ANMAT in Argentina MONTREAL, April 03, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian Company specializing in dry eye diagnosis and management, is pleased to announce receiving regulatory approval from INVIMA...

I-MED Pharma's I-PEN® Does Not Infringe the TearLab Patent MONTREAL, Feb. 20, 2018 (GLOBE NEWSWIRE) -- On February 14th TearLab issued a press release indicating it will appeal after its defeat in a patent infringement action against I-MED Pharma Inc. in...

I-MED Pharma Wins Patent Case Against TearLab MONTREAL, Feb. 13, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., announced today that TearLab’s efforts to keep the I-PEN® Osmolarity System off the market proved unsuccessful. I-MED Pharma wins...